<DOC>
	<DOCNO>NCT01016977</DOCNO>
	<brief_summary>A single-blind ( investigator-blinded ) , randomize , parallel group , single center study evaluate tolerability efficacy combination therapy Duac Gel / 0.1 % Tazorac Cream Acanya Gel / 0.1 % Tazorac Cream treatment facial acne vulgaris .</brief_summary>
	<brief_title>A Phase 4 , Single-Blind , Randomized , Study Compare Tolerability Efficacy 0.1 % Tazorac Cream When Used Combination With Either Duac Gel Acanya Gel Treatment Facial Acne Vulgaris</brief_title>
	<detailed_description>This single-blind ( investigator-blinded ) , randomize , parallel group , single center study evaluate tolerability efficacy combination therapy Duac Gel/Tazorac Cream Acanya Gel/Tazorac Cream treatment facial acne vulgaris . Approximately 40 male female subject enrol ( 20 per study group ) . Subjects participate study 12 week ; visit schedule baseline week 1 , 2 , 4 , 8 , 12 ( total 6 visit ) . Eligible subject randomize baseline 1 2 study group 1:1 ratio ( Duac Gel/Tazorac Cream Acanya Gel/Tazorac Cream ) . Subjects apply either Duac Gel Acanya Gel face morning apply Tazorac Cream face even . Tolerability evaluate subject assessment burning/stinging , itching , oiliness investigator assessment peel , erythema , dryness . In addition , subject evaluate overall skin comfort record usage moisturizer sunscreen , need . Efficacy assessed lesion count ( total , inflammatory noninflammatory ) ISGA . Safety assess evaluate adverse event ( AEs ) , concomitant medication use , withdrawal study . This investigator-blinded study ; therefore , subject study-center staff blind study treatment allocation . Subjects ( parent legal guardian ) study-center staff instruct reveal study product allocation investigator .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Documented diagnosis acne vulgaris . Lesion count : 20 50 inflammatory ( papule pustule ) 30 100 noninflammatory ( open close comedo ) facial lesion exclude nose , ≤ 1 small nodular lesion . Cystic lesion allow baseline . Investigator Static Global Assessment 3 4 Baseline . Clinically relevant find baseline medical history severe systemic disease diseases facial skin , acne vulgaris . Subjects cystic acne lesion . Facial hair may obscure accurate assessment acne grade . History presence regional enteritis inflammatory bowel disease ( eg , ulcerative colitis , pseudomembranous colitis , chronic diarrhea , celiac disease history antibioticassociated colitis ) similar symptom . Concurrent use medication know photosensitizers ( eg , thiazide , tetracycline , fluoroquinolones , phenothiazine , sulfonamide ) possibility increase phototoxicity . Concomitant use neuromuscular block agent . Clindamycin neuromuscular blocking activity , may enhance action neuromuscular blocking agent . Use topical antiacne medication ( eg , benzoyl peroxide , retinoids , azelaic acid , resorcinol , salicylate , sulfacetamide sodium derivative , glycolic acid ) within past 2 week . Use topical antibiotic face within past 2 week systemic antibiotic within past 4 week . Use topical corticosteroid face systemic corticosteroid within past 2 4 week , respectively . Use inhale , intraarticular intra lesional ( facial acne lesion ) steroid acceptable . Use systemic retinoids , Isotretinoin , within past 6 month . Concomitant use follow type facial product : astringent , toner , abradant , hair removal wax , facial , peel contain glycolic acid , mask , wash soap contain benzoyl peroxide , sulfacetamide sodium salicylic acid , nonmild facial cleanser , moisturizers contain retinol , salicylic acid , α β hydroxy acid . Concomitant use medication report exacerbate acne , ( eg , vitamins vitamin D , vitamin A , vitamins B2 , B6 , B12 ; haloperidol , halogens iodide bromide , lithium , cyclosporine , psoralen , sirolimus , imatinib , aripiprazole , isoniazid , valproate acid , hydantoin , phenobarbital ) may impact efficacy assessment . Iron supplement folate acceptable . Facial procedure ( eg , chemical peel , lasers/lights , photodynamic therapy , microdermabrasion , artificial ultraviolet therapy ) perform esthetician , beautician , physician , nurse , practitioner , within past 4 week . Known hypersensitivity previous allergic reaction component ( ) excipient ( ) study product . Use investigational medication treatment within past 4 week . Treatment estrogen , include oral , implanted topical contraceptive , androgen , antiandrogenic agent 12 week less immediately prior start study product prescribe treatment Acne Vulgaris . Subjects treat estrogen , describe , androgen , anti androgenic agent 12 consecutive week prior start study treatment allow enroll long expect change dose , medication , discontinue use study . Evidence recent alcohol drug abuse ( opinion investigator ) . Live household currently enrol subject . Employee investigator , clinical research organization , Stiefel Laboratories involve study immediate family member ( eg , partner , offspring , parent , sibling sibling 's offspring ) employee involve study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>